The Peptide Wiki
Mapping Knowledge.
Advancing Discovery.
📩 Subscribe
Last updated
Peptide Profile

Atomoxetine: Research, Dosing, and Where to Buy in 2026

A research-first profile for Atomoxetine (Strattera, Strata), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.

⚕️ US PRESCRIPTION REQUIRED. Atomoxetine is a prescription medication in the United States. Prescription and controlled-substance rules differ by country, so check your local laws before any purchase or use. Information on this page is educational and not medical advice. Consult a licensed prescribing physician.
Quick Answer

Atomoxetine is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 15 PubMed-cited papers for Atomoxetine, each linked to its source.

Key Facts
Pharmaceutical
  • Also indexed as Strattera, Strata.
  • 0 aggregated dosing-protocol mentions from source transcripts.
  • 15 PubMed-indexed citations listed in the research table below.
  • 0 vendor recommendations captured from named experts.
  • Evidence level in this entry is marked as fda_approved.
Sourced to expert
Check vendor COA
Verify dose w/ clinician

What is Atomoxetine?

Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.

What is Atomoxetine researched for?

NRI used for ADHD; questioner asked but Steve had no experience.

Atomoxetine Dosing Protocols

The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.

No transcript-derived dosing mentions in current source set.

Where to Buy Atomoxetine in 2026

No tracked vendor recommendations for Atomoxetine yet. See our vendor directory.

Side Effects and Safety

Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.

User Reviews

User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.

Research Efficacy Snapshot

Published efficacy percentages cited in PubMed trials and named-expert reports about Atomoxetine. Each line links to the original source.

  • "Key secondary endpoints were oxygen desaturation index (ODI), Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue T-score, hypoxic burden (HB), PROMIS-Sleep Impairment T-score, and proportion of participants with  ≥50% AHI reduction." · Strollo PJ et al, 2026 PubMed
  • "**MEASUREMENTS AND MAIN RESULTS**: A total of 646 eligible participants (median age 58 years, 49.3% female, median body mass index 32.4 kg/m2) were randomized." · Strollo PJ et al, 2026 PubMed
  • "Median baseline AHI was 19.6 events/hour with 35% mild, 42% moderate, and 23% severe OSA." · Strollo PJ et al, 2026 PubMed
  • "At week 26, mean AHI treatment difference was -4.0 events/hour (95% CI, -6.4 to -1.6; P = .001), representing a model-estimated 44.1% vs 17.6% decrease from baseline (P <.0001)." · Strollo PJ et al, 2026 PubMed
  • "Overall, 21.2% of participants on AD109 and 3.1% on placebo discontinued therapy due to adverse events." · Strollo PJ et al, 2026 PubMed
  • "Conversely, 50 μM ATX potently reduced progressive motility (27.8% vs." · Liu X et al, 2026 PubMed
  • "53.0% in controls at 120 min) without significantly compromising cell viability (68.9% vs." · Liu X et al, 2026 PubMed
  • "74.4%) or mitochondrial function, indicating a specific signaling disruption." · Liu X et al, 2026 PubMed
  • "Co-treatment with the PKC agonist PMA (100 nM) significantly reversed this calcium suppression (∼58%), alongside rescuing defects in motility, capacitation, and the acrosome reaction." · Liu X et al, 2026 PubMed
  • "**RESULTS**: From 2018 to 2023, OROS-MPH prescriptions significantly decreased from 64.7% to 47.5%, whereas GXR prescriptions significantly increased from 19.3% to 46.4%." · Suzuki R et al, 2026 PubMed

Research and Studies

15 PubMed-indexed papers reference Atomoxetine. Top 15 shown.

Frequently Asked Questions

Is Atomoxetine FDA-approved?

Atomoxetine is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.

How much research has been published on Atomoxetine?

15 PubMed-indexed paper(s) reference Atomoxetine in our current research feed. See the Research and Studies section above for citations.